{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:52:15Z","timestamp":1790815935513,"version":"4.1.0"},"reference-count":174,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-CE93-0003-01"],"award-info":[{"award-number":["ANR-18-CE93-0003-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["EQU201903007864"],"award-info":[{"award-number":["EQU201903007864"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.kint.2022.12.021","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:52:27Z","timestamp":1673610747000},"page":"485-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["New advances in endocrine hypertension: from genes to biomarkers"],"prefix":"10.1016","volume":"103","author":[{"given":"Fabio L.","family":"Fernandes-Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheerazed","family":"Boulkroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhta","family":"Fedlaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Hureaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Travers-Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Drossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Christina","family":"Zennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2022.12.021_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(19)31145-6","article-title":"Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.12.021_bib2","first-page":"492","article-title":"Hypertension in a family practice","volume":"117","author":"Rudnick","year":"1977","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.kint.2022.12.021_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2022.12.021_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ajh\/hpu083","article-title":"Essential hypertension vs. secondary hypertension among children","volume":"28","author":"Gupta-Malhotra","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2022.12.021_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.kint.2022.12.021_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-physiol-030220-113038","article-title":"Ion channel function and electrical excitability in the zona glomerulosa: a network perspective on aldosterone regulation","volume":"83","author":"Barrett","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1152\/physrev.00030.2003","article-title":"Control of aldosterone secretion: a model for convergence in cellular signaling pathways","volume":"84","author":"Spat","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1016\/j.kint.2022.12.021_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100191","article-title":"The role of lipid second messengers in aldosterone synthesis and secretion","volume":"63","author":"Spaulding","year":"2022","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2022.12.021_bib9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/j.2040-4603.2014.tb00565.x","article-title":"Regulation of aldosterone synthesis and secretion","volume":"4","author":"Bollag","year":"2014","journal-title":"Compr Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","article-title":"The regulation of aldosterone synthase expression","volume":"217","author":"Bassett","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib11","series-title":"Endotext. MDText.com, Inc","article-title":"ACTH action on the adrenals","author":"Angelousi","year":"2000"},{"key":"10.1016\/j.kint.2022.12.021_bib12","doi-asserted-by":"crossref","first-page":"F559","DOI":"10.1152\/ajprenal.00320.2001","article-title":"New ideas about aldosterone signaling in epithelia","volume":"282","author":"Stockand","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.ki.5002737","article-title":"Early transcriptional control of ENaC (de)ubiquitylation by aldosterone","volume":"73","author":"Verrey","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.12.021_bib14","doi-asserted-by":"crossref","first-page":"F714","DOI":"10.1152\/ajprenal.00061.2006","article-title":"Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ","volume":"291","author":"Bhalla","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MNH.0b013e32833c34ec","article-title":"Regulation and function of potassium channels in aldosterone-sensitive distal nephron","volume":"19","author":"Wang","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2022.12.021_bib16","first-page":"55","article-title":"How do glucocorticoids influence stress responses? integrating permissive, suppressive, stimulatory, and preparative actions","volume":"21","author":"Sapolsky","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.kint.2022.12.021_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tips.2013.07.003","article-title":"Glucocorticoid receptor signaling in health and disease","volume":"34","author":"Kadmiel","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"pt 1","key":"10.1016\/j.kint.2022.12.021_bib18","doi-asserted-by":"crossref","first-page":"C1343","DOI":"10.1152\/ajpcell.1996.270.5.C1343","article-title":"Corticosteroid receptor mRNA expression is unaffected by corticosteroids in rat kidney, heart, and colon","volume":"270","author":"Escoubet","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib19","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple aspects of mineralocorticoid selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib20","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/S0021-9258(18)93832-9","article-title":"Tyrosine hydroxylase: the initial step in norepinephrine biosynthesis","volume":"239","author":"Nagatsu","year":"1964","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2022.12.021_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1073\/pnas.69.2.343","article-title":"On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine)","volume":"69","author":"Christenson","year":"1972","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.12.021_bib22","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0021-9258(19)83758-4","article-title":"Purification and properties of phenylethanolamine-N-methyl transferase","volume":"237","author":"Axelrod","year":"1962","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2022.12.021_bib23","series-title":"Physiology, catecholamines","author":"Paravati","year":"2022"},{"key":"10.1016\/j.kint.2022.12.021_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4065\/77.1.45","article-title":"Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight","volume":"77","author":"Curtis","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.kint.2022.12.021_bib25","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2022.12.021_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2022.12.021_bib27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism - a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib28","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib29","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2022.12.021_bib30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.amjhyper.2006.02.002","article-title":"Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension","volume":"19","author":"Strauch","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2022.12.021_bib31","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","article-title":"Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment","volume":"29","author":"Wu","year":"2011","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2022.12.021_bib32","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2022.12.021_bib33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0031-1295412","article-title":"Primary aldosteronism and metabolic syndrome","volume":"44","author":"Fallo","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.kint.2022.12.021_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A\u00a0chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.kint.2022.12.021_bib35","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1073\/pnas.89.17.8327","article-title":"Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2","volume":"89","author":"Pascoe","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.12.021_bib36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","article-title":"Genetic characteristics of aldosterone-producing adenomas in Blacks","volume":"73","author":"Nanba","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib37","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.119.14177","article-title":"Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma","volume":"75","author":"De Sousa","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib38","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.kint.2022.12.021_bib39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","article-title":"Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma","volume":"64","author":"Fernandes-Rosa","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/HYPERTENSIONAHA.111.186239","article-title":"Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas","volume":"59","author":"Azizan","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib41","doi-asserted-by":"crossref","first-page":"E1089","DOI":"10.1210\/jc.2015-2149","article-title":"A\u00a0meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma","volume":"100","author":"Lenzini","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/HYPERTENSIONAHA.111.186478","article-title":"Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism","volume":"59","author":"Boulkroun","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib43","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2018-01004","article-title":"Targeted molecular characterization of aldosterone-producing adenomas in White Americans","volume":"103","author":"Nanba","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1530\/ERC-15-0321","article-title":"Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas","volume":"22","author":"Akerstrom","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.kint.2022.12.021_bib45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/cen.12873","article-title":"Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype","volume":"83","author":"Scholl","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.kint.2022.12.021_bib46","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1210\/jc.2014-3009","article-title":"Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance","volume":"100","author":"Cheng","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib47","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1210\/jc.2019-00531","article-title":"KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism","volume":"104","author":"Vilela","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib48","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","article-title":"A\u00a0novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism","volume":"93","author":"Geller","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19336950.2020.1761171","article-title":"A\u00a0de novo CACNA1D missense mutation in a patient with congenital hyperinsulinism, primary hyperaldosteronism and hypotonia","volume":"14","author":"De Mingo Alemany","year":"2020","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.kint.2022.12.021_bib51","doi-asserted-by":"crossref","unstructured":"T\u00f6r\u00f6k F, Tezcan K, Filippini L, et\u00a0al. Germline de novo variant F747S extends the phenotypic spectrum of CACNA1D Ca2+ channelopathies. Hum Mol Genet. Published online October 8, 2022. https:\/\/doi.org\/10.1093\/hmg\/ddac248","DOI":"10.1093\/hmg\/ddac248"},{"key":"10.1016\/j.kint.2022.12.021_bib52","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.kint.2022.12.021_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","article-title":"CACNA1H mutations are associated with different forms of primary aldosteronism","volume":"13","author":"Daniil","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2022.12.021_bib54","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.119.14349","article-title":"Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma","volume":"75","author":"Nanba","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib55","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/biomedicines9091167","article-title":"Novel mutations detection with next-generation sequencing and its association with clinical outcome in unilateral primary aldosteronism","volume":"9","author":"Wu","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.kint.2022.12.021_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041926","article-title":"Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter","volume":"7","author":"Akerstrom","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2022.12.021_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","article-title":"Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism","volume":"19","author":"Stowasser","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib58","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","article-title":"A\u00a0gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism","volume":"50","author":"Fernandes-Rosa","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/a-0713-0629","article-title":"Inherited forms of primary hyperaldosteronism: new genes, new phenotypes and proposition of a new classification","volume":"127","author":"Perez-Rivas","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.kint.2022.12.021_bib61","doi-asserted-by":"crossref","first-page":"K37","DOI":"10.1530\/EJE-19-0377","article-title":"A\u00a0somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma","volume":"181","author":"Dutta","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib62","doi-asserted-by":"crossref","first-page":"bvaa123","DOI":"10.1210\/jendso\/bvaa123","article-title":"Identification of somatic mutations in CLCN2 in aldosterone-producing adenomas","volume":"4","author":"Rege","year":"2020","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.kint.2022.12.021_bib63","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1038\/s41467-019-12113-9","article-title":"Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism","volume":"10","author":"G\u00f6ppner","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2022.12.021_bib64","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.2716","article-title":"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension","volume":"45","author":"Azizan","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib66","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1504869","article-title":"Pregnancy, primary aldosteronism, and adrenal CTNNB1 mutations","volume":"373","author":"Teo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.12.021_bib67","article-title":"The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2022.12.021_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/srep19546","article-title":"Activating mutations in CTNNB1 in aldosterone producing adenomas","volume":"6","author":"Akerstrom","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2022.12.021_bib69","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41588-021-00906-y","article-title":"Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause","volume":"53","author":"Zhou","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib70","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/en.2013-1944","article-title":"Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas","volume":"155","author":"Tauber","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2022.12.021_bib71","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","article-title":"Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma","volume":"127","author":"Scholl","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2022.12.021_bib72","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/HYPERTENSIONAHA.117.10226","article-title":"Macrolides blunt aldosterone biosynthesis: a proof-of-concept study in KCNJ5 mutated adenoma cells ex\u00a0vivo","volume":"70","author":"Caroccia","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib73","series-title":"Macrolides for KCNJ5-mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism","first-page":"200","volume":"27","author":"Maiolino","year":"2018"},{"key":"10.1016\/j.kint.2022.12.021_bib74","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/HYPERTENSIONAHA.115.06186","article-title":"Genotype-specific steroid profiles associated with aldosterone-producing adenomas","volume":"67","author":"Williams","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.12.021_bib75","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1038\/s41467-022-32896-8","article-title":"Identification of risk loci for primary aldosteronism in genome-wide association studies","volume":"13","author":"Le Floch","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2022.12.021_bib76","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/CIRCULATIONAHA.109.904664","article-title":"Blood pressure and hypertension are associated with 7 loci in the Japanese population","volume":"121","author":"Takeuchi","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2022.12.021_bib77","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajh\/hpz150","article-title":"Genome-wide association study of apparent treatment-resistant hypertension in the CHARGE Consortium: the CHARGE Pharmacogenetics Working Group","volume":"32","author":"Irvin","year":"2019","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kint.2022.12.021_bib78","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/EJE-21-0338","article-title":"Somatic mutations in adrenals from patients with primary aldosteronism not cured after adrenalectomy suggest common pathogenic mechanisms between unilateral and bilateral disease","volume":"185","author":"Hacini","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib79","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1681\/ASN.2006060570","article-title":"Apparent mineralocorticoid excess: report of six new cases and extensive personal experience","volume":"17","author":"Morineau","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.12.021_bib80","doi-asserted-by":"crossref","first-page":"E11248","DOI":"10.1073\/pnas.1716621115","article-title":"Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11\u03b2-hydroxysteroid dehydrogenase type 2 deficiency","volume":"114","author":"Yau","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.12.021_bib81","first-page":"2244","article-title":"Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess","volume":"83","author":"Dave-Sharma","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib82","first-page":"2263","article-title":"A\u00a0mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess","volume":"80","author":"Wilson","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib83","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"issue":"pt A","key":"10.1016\/j.kint.2022.12.021_bib84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jsbmb.2016.02.002","article-title":"Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic\u00a0and pharmacologic","volume":"165","author":"Auchus","year":"2017","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.kint.2022.12.021_bib85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12020-021-02966-w","article-title":"High incidence of hypertension-mediated organ damage in a series of Chinese patients with 17\u03b1-hydroxylase deficiency","volume":"76","author":"Zhao","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.kint.2022.12.021_bib86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0889-8529(08)70021-5","article-title":"The genetics, pathophysiology, and management of human deficiencies of P450c17","volume":"30","author":"Auchus","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.kint.2022.12.021_bib87","doi-asserted-by":"crossref","unstructured":"Sun B, Lu L, Gao Y, et\u00a0al. High prevalence of hypertension and target organ damage in patients with 11\u03b2-hydroxylase deficiency. Clin Endocrinol (Oxf). Published online January 24, 2022. https:\/\/doi.org\/10.1111\/cen.14677","DOI":"10.1111\/cen.14677"},{"key":"10.1016\/j.kint.2022.12.021_bib88","doi-asserted-by":"crossref","first-page":"e3714","DOI":"10.1210\/clinem\/dgab225","article-title":"Clinical and hormonal profiles correlate with molecular characteristics in patients with 11\u03b2-hydroxylase deficiency","volume":"106","author":"Yildiz","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib89","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.kint.2022.12.021_bib90","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/en.2002-220708","article-title":"The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related","volume":"144","author":"Rafestin-Oblin","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2022.12.021_bib91","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ando.2022.02.001","article-title":"Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing\u2019s syndrome","volume":"83","author":"Tabarin","year":"2022","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.kint.2022.12.021_bib92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11102-019-00951-1","article-title":"The incidence of Cushing\u2019s disease: a nationwide Swedish study","volume":"22","author":"Ragnarsson","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.kint.2022.12.021_bib93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/cen.14014","article-title":"The incidence of endogenous Cushing\u2019s syndrome in the modern era","volume":"91","author":"Wengander","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.kint.2022.12.021_bib94","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib95","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1210\/jc.2016-1673","article-title":"A\u00a0probabilistic model for Cushing\u2019s syndrome screening in at-risk populations: a prospective multicenter study","volume":"101","author":"Le\u00f3n-Justel","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib96","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing\u2019s syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.12.021_bib97","first-page":"e426","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2022.12.021_bib98","series-title":"2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","first-page":"314","volume":"27","author":"Williams","year":"2018"},{"key":"10.1016\/j.kint.2022.12.021_bib99","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing\u2019s syndrome: 2-year experience: baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib100","first-page":"3617","article-title":"11 beta-Hydroxysteroid dehydrogenase activity in Cushing\u2019s syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome","volume":"80","author":"Stewart","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1210\/jcem-62-2-275","article-title":"Multiple factors contribute to the pathogenesis of hypertension in Cushing\u2019s syndrome","volume":"62","author":"Saruta","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib102","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1530\/eje.0.1490549","article-title":"Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing\u2019s syndrome","volume":"149","author":"Kirilov","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib103","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1440-1681.1998.tb02349.x","article-title":"The nitric oxide system and cortisol-induced hypertension in humans","volume":"25","author":"Kelly","year":"1998","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.kint.2022.12.021_bib104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fendo.2019.00321","article-title":"The pathophysiology and treatment of hypertension in patients with Cushing\u2019s syndrome","volume":"10","author":"Barbot","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.kint.2022.12.021_bib105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib106","first-page":"104","article-title":"Cushing disease due to a somatic USP8 mutation in a patient with evolving pituitary hormone deficiencies due to a germline GH1 splicing variant","volume":"66","author":"Labello","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib107","doi-asserted-by":"crossref","first-page":"E997","DOI":"10.1210\/jc.2015-1453","article-title":"The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing\u2019s disease","volume":"100","author":"Perez-Rivas","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib108","doi-asserted-by":"crossref","first-page":"e3346","DOI":"10.1210\/clinem\/dgab387","article-title":"Two distinctive POMC promoters modify gene expression in Cushing disease","volume":"106","author":"Araki","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib109","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa507","article-title":"The clinical features and molecular mechanisms of ACTH-secreting pancreatic neuroendocrine tumors","volume":"105","author":"Zhang","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1677\/joe.1.05963","article-title":"Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids","volume":"185","author":"Ye","year":"2005","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib111","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2796.1998.00275.x","article-title":"Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1","volume":"243","author":"Burgess","year":"1998","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.kint.2022.12.021_bib112","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verg\u00e8s","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib113","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1210\/jc.2006-2843","article-title":"Germline CDKN1B\/p27Kip1 mutation in multiple endocrine neoplasia","volume":"92","author":"Georgitsi","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib114","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1210\/jc.2005-2671","article-title":"Clinical characterization of familial isolated pituitary adenomas","volume":"91","author":"Daly","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib115","first-page":"2728","article-title":"Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors","volume":"86","author":"Korbonits","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib116","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1073\/pnas.96.4.1439","article-title":"The molecular chaperone\u00a0Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter","volume":"96","author":"Kang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.12.021_bib117","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3776","article-title":"A\u00a0C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease","volume":"21","author":"Riebold","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2022.12.021_bib118","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/endrev\/bnab046","article-title":"Molecular derangements and the diagnosis of ACTH-dependent Cushing\u2019s syndrome","volume":"43","author":"Nieman","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.kint.2022.12.021_bib119","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ecl.2018.02.007","article-title":"Genetics of Cushing\u2019s syndrome","volume":"47","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.kint.2022.12.021_bib120","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.12.021_bib121","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/79238","article-title":"Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex","volume":"26","author":"Kirschner","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib122","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1310359","article-title":"Constitutive activation of PKA catalytic subunit in adrenal Cushing\u2019s syndrome","volume":"370","author":"Beuschlein","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.12.021_bib123","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1126\/science.1249480","article-title":"Activating hotspot L205R mutation in PRKACA and adrenal Cushing\u2019s syndrome","volume":"344","author":"Cao","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.kint.2022.12.021_bib124","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2956","article-title":"Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors","volume":"46","author":"Goh","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib125","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1126\/science.1252328","article-title":"Recurrent somatic mutations underlie corticotropin-independent Cushing\u2019s syndrome","volume":"344","author":"Sato","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.kint.2022.12.021_bib126","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng1809","article-title":"A\u00a0genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in\u00a0individuals with adrenocortical hyperplasia","volume":"38","author":"Horvath","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib127","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJMc0706182","article-title":"Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia","volume":"358","author":"Horvath","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.12.021_bib128","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/hmg\/ddq029","article-title":"Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development","volume":"19","author":"Berthon","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2022.12.021_bib129","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1210\/jc.2008-0631","article-title":"Wnt\/beta-catenin and 3\u2019,5\u2019-cyclic adenosine 5\u2019-monophosphate\/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors","volume":"93","author":"Gaujoux","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2265.2007.03033.x","article-title":"Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas","volume":"68","author":"Tadjine","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.kint.2022.12.021_bib131","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","article-title":"Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors","volume":"65","author":"Tissier","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.kint.2022.12.021_bib132","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/ERC-20-0128","article-title":"Genomic classification of benign adrenocortical lesions","volume":"28","author":"Faillot","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.kint.2022.12.021_bib133","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMoa1304603","article-title":"ARMC5 mutations in macronodular adrenal hyperplasia with Cushing\u2019s syndrome","volume":"369","author":"Assi\u00e9","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.12.021_bib134","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12920-021-00896-0","article-title":"A\u00a0novel nonsense mutation in ARMC5 causes primary bilateral macronodular adrenocortical hyperplasia","volume":"14","author":"He","year":"2021","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.kint.2022.12.021_bib135","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12020-021-02645-w","article-title":"Update on primary bilateral macronodular adrenal hyperplasia (PBMAH)","volume":"71","author":"Bouys","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.kint.2022.12.021_bib136","doi-asserted-by":"crossref","first-page":"E1784","DOI":"10.1210\/jc.2014-1265","article-title":"ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia","volume":"99","author":"Gagliardi","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib137","doi-asserted-by":"crossref","first-page":"E1501","DOI":"10.1210\/jc.2013-4237","article-title":"ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia","volume":"99","author":"Alencar","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib138","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/EJE-21-1032","article-title":"Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients","volume":"187","author":"Bouys","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib139","doi-asserted-by":"crossref","first-page":"E926","DOI":"10.1210\/jc.2014-4204","article-title":"ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences","volume":"100","author":"Espiard","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mce.2017.06.027","article-title":"The role of ARMC5 in human cell cultures from nodules of primary macronodular adrenocortical hyperplasia (PMAH)","volume":"460","author":"Cavalcante","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.2009.03689.x","article-title":"Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction","volume":"73","author":"Lacroix","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.kint.2022.12.021_bib142","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1530\/EJE-10-0195","article-title":"Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing\u2019s syndrome","volume":"163","author":"Lib\u00e9","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib143","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-8587(21)00236-9","article-title":"Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing\u2019s syndrome: a multicentre, retrospective, cohort study","volume":"9","author":"Chasseloup","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib144","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.gim.2021.09.018","article-title":"KDM1A inactivation causes hereditary food-dependent Cushing syndrome","volume":"24","author":"Vaczlavik","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2022.12.021_bib145","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199210013271402","article-title":"Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing\u2019s syndrome","volume":"327","author":"Lacroix","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.12.021_bib146","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/EJE-21-0907","article-title":"Identification of glucocorticoid-related molecular signature by whole blood methylome analysis","volume":"186","author":"Armignacco","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib147","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2217\/epi-2017-0057","article-title":"FKBP5 methylation as a possible marker for cortisol state and transient cortisol exposure in healthy human subjects","volume":"9","author":"Winkler","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.kint.2022.12.021_bib148","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99714-x","article-title":"HPA axis dysregulation is associated with differential methylation of CpG-sites in related genes","volume":"11","author":"Chatzittofis","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2022.12.021_bib149","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eprac.2021.06.012","article-title":"Osilodrostat: a review of recent clinical studies and practical recommendations for its use in the treatment of Cushing disease","volume":"27","author":"Yuen","year":"2021","journal-title":"Endocr Pract"},{"key":"10.1016\/j.kint.2022.12.021_bib150","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing\u2019s syndrome due to adrenocortical carcinomas","volume":"186","author":"Tabarin","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib151","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cpdd.389","article-title":"Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study","volume":"7","author":"Hunt","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.kint.2022.12.021_bib152","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing\u2019s syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib153","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.2002.tb04416.x","article-title":"Familial\/sporadic glucocorticoid resistance syndrome and hypertension","volume":"970","author":"Kino","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.kint.2022.12.021_bib154","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1210\/jc.2008-0040","article-title":"Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder","volume":"93","author":"Charmandari","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib155","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib156","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1210\/jc.2004-1398","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib157","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ecl.2011.02.002","article-title":"Hypertension in pheochromocytoma: characteristics and treatment","volume":"40","author":"Zuber","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.kint.2022.12.021_bib158","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1245\/s10434-020-08221-2","article-title":"Update on pheochromocytoma and paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, part 2 of 2: perioperative management and outcomes of pheochromocytoma and paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.kint.2022.12.021_bib159","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40200-016-0226-x","article-title":"Does this patient have pheochromocytoma? a systematic review of clinical signs and symptoms","volume":"15","author":"Soltani","year":"2015","journal-title":"J\u00a0Diabetes Metab Disord"},{"key":"10.1016\/j.kint.2022.12.021_bib160","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib161","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/EJE-19-0159","article-title":"Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion","volume":"181","author":"Geroula","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib162","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.4158\/EP171877.OR","article-title":"Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.kint.2022.12.021_bib163","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.kint.2022.12.021_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib165","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.12.021_bib166","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2014.01.001","article-title":"Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment","volume":"38","author":"Martucci","year":"2014","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.kint.2022.12.021_bib167","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1515\/enr-2017-0018","article-title":"Pheochromocytoma, diagnosis and treatment: review of the literature","volume":"51","author":"Farrugia","year":"2017","journal-title":"Endocr Regul"},{"key":"10.1016\/j.kint.2022.12.021_bib168","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/ijms23031450","article-title":"Genetics of pheochromocytomas and paragangliomas determine the therapeutical approach","volume":"23","author":"Sarkadi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.12.021_bib169","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41440-020-0531-0","article-title":"Recent advances in the management of pheochromocytoma and paraganglioma","volume":"43","author":"Tanabe","year":"2020","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2022.12.021_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104276","article-title":"Machine learning for classification of hypertension subtypes using multi-omics: a multi-centre, retrospective, data-driven study","volume":"84","author":"Reel","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2022.12.021_bib171","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1210\/clinem\/dgaa954","article-title":"Targeted metabolomics as a tool in discriminating endocrine from primary hypertension","volume":"106","author":"Erlic","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2022.12.021_bib172","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/metabo12080755","article-title":"Predicting hypertension subtypes with machine learning using targeted metabolites and their ratios","volume":"12","author":"Reel","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.kint.2022.12.021_bib173","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16209","article-title":"Use of steroid profiling combined with machine learning for identification and subtype classification in primary aldosteronism","volume":"3","author":"Eisenhofer","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kint.2022.12.021_bib174","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13148-022-01347-y","article-title":"Whole blood methylome-derived features to discriminate endocrine hypertension","volume":"14","author":"Armignacco","year":"2022","journal-title":"Clin Epigenet"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:05:22Z","timestamp":1758762322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":174,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0085253823000091"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.12.021","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New advances in endocrine hypertension: from genes to biomarkers","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}